Articles citing this paper
Initiation and maintenance of statins and aspirin after acute coronary syndromes (ANZACS-QI 11)
Andrew J. Kerr 1 , Mansi Turaga 2 , Corina Grey 3 , Mildred Lee 2 , Andrew McLachlan 2 , Gerry Devlin 4
+ Author Affiliations
- Author Affiliations
1 Counties Manukau District Health Board; and University of Auckland, New Zealand
2 Counties Manukau District Health Board, New Zealand
3 Section of Epidemiology and Biostatistics, University of Auckland, New Zealand
4 Waikato District Health Board and University of Auckland, New Zealand; and National Heart Foundation, New Zealand
Correspondence to: Andrew J. Kerr, Department of Cardiology, Middlemore Hospital, Otahuhu, Auckland 93311, New Zealand. Email: Andrew.Kerr@middlemore.co.nz
Journal of Primary Health Care 8(3) 238-249 https://doi.org/10.1071/HC16013
Published: 20 September 2016
10 articles found in Crossref database.
Clinical consequences of poor adherence to lipid-lowering therapy in patients with cardiovascular disease: can we do better?
Klimis Harry, Chow Clara K
Heart Asia. 2019 11(2). p.e011200
Underuse of beta‐blockers by patients with COPD and co‐morbid acute coronary syndrome: A nationwide follow‐up study in New Zealand
Parkin Lianne,
Quon Joshua,
Sharples Katrina,
Barson David, Dummer Jack
Respirology. 2020 25(2). p.173
Estimating the economic impact of acute coronary syndrome in New Zealand over time (ANZACS-QI 64): a national registry-based cost burden study
Lee Peter,
Kerr AJ,
Jiang Yannan,
Zomer Ella, Liew Danny
BMJ Open. 2022 12(8). p.e056405
A Risk Model to Predict Statin Non-Adherence Following an Acute Coronary Syndrome
Liao Yi-Wen (Becky),
Lee Mildred,
Poppe Katrina K.,
Kerr Andrew J., Stewart Ralph A.H.
Heart, Lung and Circulation. 2023 32(5). p.612
What is the Statin Possession Ratio Cut-Off Which Identifies Those at Increased Risk Following Acute Coronary Syndrome (ANZACS-QI 68)?
Ali Morisha,
Kerr Andrew J.,
Lee Mildred, Chan Daniel Z.L.
Heart, Lung and Circulation. 2023 32(4). p.487
Statin adherence is lower in primary than secondary prevention: A national follow-up study of new users
Sigglekow Finn,
Horsburgh Simon,
Parkin Lianne, Gall Seana
PLOS ONE. 2020 15(11). p.e0242424
Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24
Kasargod Chethan,
Devlin Gerry,
Lee Mildred,
White Harvey D., Kerr Andrew J.
Heart, Lung and Circulation. 2020 29(6). p.824
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome
Lv Wen-He,
Dong Jian-Zeng,
Du Xin,
Hu Rong,
He Liu,
Long De-Yong,
Sang Cai-Hua,
Jia Chang-Qi,
Feng Li,
Li Xu,
Ning Man,
Chen Xuan,
Cui Yi-Kai,
Tang Ri-Bo, Ma Chang-Sheng
Journal of Thrombosis and Thrombolysis. 2022 53(4). p.868
What are the gaps in cardiovascular risk assessment and management in primary care for Māori and Pacific people in Aotearoa New Zealand? Protocol for a systematic review
Brewer Karen Marie,
Grey Corina,
Paynter Janine,
Winter-Smith Julie,
Hanchard Sandra,
Selak Vanessa,
Ameratunga Shanthi, Harwood Matire
BMJ Open. 2022 12(6). p.e060145
An Economic Evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry Program (ANZACS-QI 28)
Lee Peter,
Zomer Ella, Liew Danny
Heart, Lung and Circulation. 2020 29(7). p.1046
